<PAGE> 1
FORM 10-Q/A-1
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED
AUGUST 27, 1994 OR
---------------------------
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM
TO
---------------------- ----------------------
Commission File Number 0-16998
-----------
DRUG EMPORIUM, INC.
- --------------------------------------------------------------------------------
(Exact name of registrant as specified in its charter)
DELAWARE 31-1064888
- -----------------------------------------------------------------------------
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)
155 HIDDEN RAVINES DRIVE, POWELL, OHIO 43065
- -----------------------------------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (614) 548-7080
---------------------------
_____________________________________________________________________________
Former name, former address and former fiscal year, if changed since last
report.
Indicate by check mark whether the registrant: (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days.
Yes X No
--- ---
Indicate the number of shares outstanding of each of the issuer's classes of
common stock, as of the close of the period covered by this report.
CLASS Outstanding at 8/27/94
- ---------------------------- -----------------
Common Stock, $.10 par value 13,170,585 shares
---------------
The undersigned Registrant hereby amends the following items, financial
statements, exhibits or other portions of its Quarterly Report on Form 10-Q for
the quarterly period ended August 27, 1994 as set forth in the pages attached
hereto:
<PAGE> 2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this amendment to be signed on its behalf by the
undersigned thereunto duly authorized.
DRUG EMPORIUM, INC.
---------------------------------
(Registrant)
Date January 6, 1995 By /s/ David L. Kriegel
------------------------ -----------------------------------
David L. Kriegel
Chairman
Chief Executive Officer
Date January 6, 1995 By /s/ Timothy S. McCord
------------------------ ------------------------------------
Timothy S. McCord
Chief Financial Officer
<PAGE> 3
Exhibit Index
Official
Exhibit Number Description
- -------------- -----------
11* Statement Re: Computation
of earnings per share
27 Financial Data Schedule
*Previously filed
<TABLE> <S> <C>
<ARTICLE> 5
<MULTIPLIER> 1,000
<CURRENCY> U.S. DOLLARS
<S> <C>
<PERIOD-TYPE> 6-MOS
<FISCAL-YEAR-END> FEB-25-1995
<PERIOD-START> FEB-27-1994
<PERIOD-END> AUG-27-1994
<EXCHANGE-RATE> 1
<CASH> 833
<SECURITIES> 0
<RECEIVABLES> 11,271
<ALLOWANCES> 0
<INVENTORY> 151,936
<CURRENT-ASSETS> 167,285
<PP&E> 57,505
<DEPRECIATION> 29,860
<TOTAL-ASSETS> 201,898
<CURRENT-LIABILITIES> 83,910
<BONDS> 65,952
<COMMON> 1,317
0
0
<OTHER-SE> 50,719
<TOTAL-LIABILITY-AND-EQUITY> 201,898
<SALES> 372,847
<TOTAL-REVENUES> 372,847
<CGS> 294,784
<TOTAL-COSTS> 368,685
<OTHER-EXPENSES> 0
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 3,340
<INCOME-PRETAX> 822
<INCOME-TAX> 325
<INCOME-CONTINUING> 497
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> 497
<EPS-PRIMARY> .04
<EPS-DILUTED> .04
</TABLE>
